Advanz Pharma (OTCMKTS:CXRXF) posted its quarterly earnings data on Wednesday. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.03, Morningstar.com reports. The business had revenue of $131.08 million during the quarter, compared to analysts’ expectations of $127.00 million.
Shares of CXRXF remained flat at $$11.59 during trading hours on Friday. The company had a trading volume of 1 shares, compared to its average volume of 321. The company has a quick ratio of 1.71, a current ratio of 2.01 and a debt-to-equity ratio of 6.47. Advanz Pharma has a 52-week low of $11.59 and a 52-week high of $56.70. The stock has a market capitalization of $566.87 million, a price-to-earnings ratio of 0.98 and a beta of 0.50. The company has a 50-day simple moving average of $14.95.
Several brokerages recently commented on CXRXF. Zacks Investment Research cut Advanz Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 15th. ValuEngine upgraded Advanz Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
Read More: Why do analysts give a neutral rating?
Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.